2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events A 2024 Meta-analysis of 13 multiple cardiovascular outcome trials has documented that GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
SURPASS 2 trial- Semaglutide versus tirzepatide for diabetes (Hba1c and fasting glucose levels) Both Semaglutide (Ozempic) and Tirzepatide are effective treatments for diabetes, helping to lower Hba1c and fasting blood glucose levels effectively
Why would Wegovy modify your sex drive
Steward is among users who have shared their experiences of the drug with Insider
Afua, who lives in the UK, also struggled with her weight and fertility
There was a large overlap in the exposure at the two doses, and exposure was generally similar at the same dose level between trials (Fig
